Jaiprakash Associates down after earnings disappoint

Tue Feb 12, 2013 10:56am IST

People watch a news channel displayed on a large screen on the facade of the Bombay Stock Exchange building, February 28, 2007. REUTERS/Arko Datta/Files

People watch a news channel displayed on a large screen on the facade of the Bombay Stock Exchange building, February 28, 2007.

Credit: Reuters/Arko Datta/Files

Related Topics

Stocks

   

Reuters Market Eye - Shares in Jaiprakash Associates Ltd (JAIA.NS) fell as much as 4.2 percent, a day after the company reported a 64.2 percent fall in Oct-Dec net profit to 1.11 billion rupees.

The company reported a 17 percent rise in cement volumes to 3.7 million metric tonnes for the quarter, Barclays said in a note. However, EBITDA realisation came down 19 percent over the period due to higher fuel and logistics costs, mitigating the advantage of higher cement volumes.

Finance costs rose 15 percent although earnings were supported by high quarterly real-estate sales, it added.

"Near-term stock performance would be driven by JPA's ability to resolve perception around debt service capability," the note said, adding it expects clarity on sale of Gujarat cement plants to ease near-term debt concerns.

(Reporting by Manoj Dharra)

FILED UNDER:

Monetary Policy Committee

Reuters Showcase

Microfinance

Microfinance

Funding the unfunded: India helps small business borrow to grow  Full Article 

Insurance Sector

Insurance Sector

UK healthcare firm Bupa sees strong growth in India  Full Article 

Sensex Rises

Sensex Rises

Sensex edges up; consumer and healthcare stocks rise  Full Article 

Market Eye

Market Eye

FTSE adds nine Indian firms as large-caps in Asia-Pacific ex-Japan index   Full Article 

Indian Ocean Diplomacy

Indian Ocean Diplomacy

PM Modi to ramp up help for Indian Ocean nations to counter China influence  Full Article 

ECB Bond-Buying

ECB Bond-Buying

ECB raises growth forecasts, to start printing money next week  Full Article 

China Economy

China Economy

China signals "new normal" with lower annual growth target  Full Article 

Pharma Sector

Pharma Sector

Panel recommends waiving late-stage trials for some drugs  Full Article 

E-commerce

E-commerce

China backs e-commerce expansion in win for Alibaba, JD.com  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device  Full Coverage